PUBLIC COMPANY
save$KYMRKymera Therapeutics, Inc.
$KYMR107.39-2.48%Watertown, MA, USupdated 19h ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
2
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 2
Upcoming
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis
- phase2A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma
- phase1First-in-human Study of Orally Administered KT-579 in Healthy Adult Participants
- phase1Safety, PK, PD, and Clinical Activity of Orally Administered KT-621 in Adult Patients With Atopic Dermatitis (AD)
- phase1First-in-human Study of Orally Administered KT-621 in Healthy Adult Participants
- phase1Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors
- phase1Safety and Clinical Activity of KT-253 in Adult Patients with High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors
- phase1Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients with Relapsed or Refractory B-cell NHL
Insider activity
source: SEC Form 4open-market buys + sells
- Apr 22, 26SELLBooth Bruce· −$531K↗
- Apr 22, 26SELLChadwick Jeremy G· Chief Operating Officer−$27K↗
- Apr 22, 26SELLBooth Bruce· −$8K↗
- Apr 22, 26SELLBooth Bruce· −$1K↗
- Apr 15, 26SELLBooth Bruce· −$248K↗
- Apr 15, 26SELLBooth Bruce· −$198K↗
- Apr 15, 26SELLChadwick Jeremy G· Chief Operating Officer−$117K↗
- Apr 15, 26SELLBooth Bruce· −$35K↗
- Apr 14, 26SELLChadwick Jeremy G· Chief Operating Officer−$473K↗
- Apr 14, 26SELLBooth Bruce· −$374K↗
- Apr 14, 26SELLGoodman Noah· Chief Business Officer−$121K↗
- Apr 10, 26SELLGoodman Noah· Chief Business Officer−$175K↗
- Apr 9, 26SELLGoodman Noah· Chief Business Officer−$268K↗
- Apr 9, 26SELLGoodman Noah· Chief Business Officer−$233K↗
- Apr 9, 26SELLGoodman Noah· Chief Business Officer−$223K↗
routine RSU / option mechanics (5)
- Apr 22, 26option exerciseBooth Bruce · 5,641 sh
- Apr 22, 26option exerciseChadwick Jeremy G · Chief Operating Officer200 sh
- Apr 22, 26option exerciseBooth Bruce · 259 sh
- Apr 22, 26option exerciseChadwick Jeremy G · Chief Operating Officer100 sh
- Apr 22, 26option exerciseBooth Bruce · 5,641 sh
🐶 Hiring Signal
next earnings Nov 3, 2026
Where Kymera Therapeutics, Inc. is staffing up — a leading indicator of pipeline and commercial priorities.
therapeutic areaImmunology & Inflammation 29
News
- 6 immunology targets to sustain a mammoth I&I marketJohnson & Johnson, Pfizer, Argenx and more are unlocking new immunology targets and looking to improve on existing ones in an attempt to catch some of the magic brought about by AbbVie’s Humira and…biospace · 6d ago
- North Immunology joins biotech reverse merger boom with Aethlon dealArmed with $180 million and a dual-acting antibody for eczema, the startup is capitalizing on a change in sentiment that’s led to a sudden spike in reverse merger deals.biopharma_dive · 16d ago
- Chutes & Ladders—Legend CEO departs without successor in placeLegend Biotech CEO Ying Huang, Ph.D., has left the company suddenly, without a predecessor in place. Huang was elevated from CFO to CEO in 2020 after a Chinese customs investigation was opened on f…fiercebiotech · 2mo ago
Data sources
last refreshed 28m ago
Found something off?
comments(0)
5-min edit window · permanent after that